J. M. Moll, I. Haslock, I. F. Macrae, and V. Wright, Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome

, Medicine (Baltimore), vol.53, pp.343-64, 1974.

C. Stolwijk, M. Van-onna, A. Boonen, and A. Van-tubergen, Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis, Arthritis Care Res, vol.68, issue.9, pp.1320-1351, 2016.

K. Lehtinen, Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis, Ann Rheum Dis, vol.52, issue.3, pp.174-180, 1993.

C. Prati, P. Claudepierre, T. Pham, and D. Wendling, Mortality in spondylarthritis. Jt Bone Spine Rev Rhum, vol.78, pp.466-70, 2011.

Á. Machado-ma-de, M. M. Barbosa, A. M. Almeida, V. E. De-araújo, A. M. Kakehasi et al., Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis

, Rheumatol Int, vol.33, issue.9, pp.2199-213, 2013.

C. Antoni, G. G. Krueger, K. De-vlam, C. Birbara, A. Beutler et al., Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial, Ann Rheum Dis, vol.64, issue.8, pp.1150-1157, 2005.

J. Braun and J. Sieper, Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-? therapy and other novel approaches, Arthritis Res, vol.4, issue.5, pp.307-328, 2002.

J. Sieper, New treatment targets for axial spondyloarthritis, Rheumatol Oxf Engl, 2016.

C. L. Krieckaert and W. F. Lems, Are we ready for therapeutic drug monitoring of biologic therapeutics?, Arthritis Res Ther, vol.13, issue.4, p.120, 2011.

Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson et al., Population pharmacokinetics of infliximab in patients with ankylosing spondylitis, J Clin Pharmacol, 2008.

T. Jurado, C. Plasencia-rodríguez, A. Martínez-feito, V. Navarro-compán, T. Rispens et al., Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients, Open Rheumatol J, vol.11, pp.75-87, 2017.

M. K. De-vries, G. J. Wolbink, S. O. Stapel, E. R. De-groot, B. Dijkmans et al.,

, Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation, Ann Rheum Dis, vol.66, issue.1, pp.133-137, 2007.

M. K. De-vries, G. J. Wolbink, S. O. Stapel, H. De-vrieze, J. C. Van-denderen et al., Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Ann Rheum Dis, vol.66, issue.9, pp.1252-1256, 2007.

E. Ducourau, D. Mulleman, G. Paintaud, M. Lin, D. C. Lauféron et al.,

, Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases, Arthritis Res Ther, 2011.

, Jun, vol.27, issue.3, p.105

E. Dreesen, P. Bossuyt, D. Mulleman, A. Gils, and D. Pascual-salcedo, Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases, Clin Pharmacol Adv Appl, vol.9, pp.101-112, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01980768

F. B. Vincent, E. F. Morand, K. Murphy, F. Mackay, X. Mariette et al., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective, Ann Rheum Dis, 2013.

K. Bendtzen, Anti-TNF-? biotherapies: perspectives for evidence-based personalized medicine, Immunotherapy, vol.4, issue.11, pp.1167-79, 2012.

J. G. Sanchez-hernandez, N. Rebollo, F. Muñoz, A. Martin-suarez, and M. V. Calvo, ANNALS EXPRESS: Therapeutic drug monitoring of TNF inhibitors in the management of chronic inflammatory diseases, Ann Clin Biochem, 2018.

S. Garcês, M. Antunes, E. Benito-garcia, J. C. Silva, L. Aarden et al., A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies, Ann Rheum Dis, 2014.

F. Medina, C. Plasencia, P. Goupille, G. Paintaud, A. Balsa et al., Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis, Ther Drug Monit, vol.39, issue.4, pp.360-363, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01980745

M. Rudwaleit, D. Van-der-heijde, R. Landewé, N. Akkoc, J. Brandt et al., The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general, Ann Rheum Dis, vol.70, issue.1, pp.25-31, 2011.

M. Rudwaleit, R. Landewé, . Heijde-d-van-der, J. Listing, J. Brandt et al., The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal, Ann Rheum Dis, vol.68, issue.6, pp.770-776, 2009.

W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease et al.,

, Classification criteria for psoriatic arthritis: development of new criteria from a large international study, Arthritis Rheum, vol.54, issue.8, pp.2665-73, 2006.

S. Garrett, T. Jenkinson, L. G. Kennedy, H. Whitelock, P. Gaisford et al., A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index, J Rheumatol, vol.21, issue.12, 1994.

E. Schmitz, D. Van-de-kerkhof, D. Hamann, J. Van-dongen, and P. Kuijper,

L. Brunsveld, REFERENCES REFERENCES and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study, Clin Chem Lab Med, vol.54, issue.7, pp.346-54, 2016.

W. Park, D. H. Yoo, J. Jaworski, J. Brzezicki, A. Gnylorybov et al., Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study, Arthritis Res Ther, vol.18, p.25, 2016.

P. Goupille,

, Rev Med Interne, vol.37, issue.5, pp.343-352, 2016.

M. Zisapel, D. Zisman, N. Madar-balakirski, U. Arad, H. Padova et al.,

, Prevalence of TNF-? blocker immunogenicity in psoriatic arthritis, J Rheumatol, 2015.

E. L. Kneepkens, J. Wei, M. T. Nurmohamed, K. Yeo, C. Y. Chen et al.,

I. E. Bruinsma, Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up, Ann Rheum Dis, vol.74, issue.2, pp.396-401, 2015.

J. E. Paramarta and D. L. Baeten, Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation, Arthritis Res Ther, vol.16, issue.4, p.160, 2014.

C. Plasencia, E. L. Kneepkens, G. Wolbink, C. Krieckaert, S. Turk et al., Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity, J Rheumatol, 2015.